Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.
User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.
The conversation discusses progress with a hair loss treatment regimen that includes once daily topical Finasteride, Pyrilutamide, and WAY-316606. Specific treatments for hair loss are being shared and discussed.
The conversation discusses a botanically derived treatment for androgenetic alopecia using ingredients like saw palmetto, green tea, and evening primrose, showing impressive results over 270 days. Concerns include the study's uncontrolled nature and potential product motivation, with suggestions to enhance absorption through derma rolling.
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.
Follicusan DP is discussed as a potential alternative to Minoxidil without side effects, but information is scarce. It is noted to be of German origin and details on its mechanism are limited.
People are discussing obtaining and testing PP405 for hair loss treatment, with concerns about its purity and effectiveness. Some are considering delaying hair transplants, while others suggest using existing treatments like finasteride and minoxidil.
Pyrilutamide, a potential hair loss treatment that has been tested in Phase 2 trials and may be available for purchase through a group buy in June. It is purported to have similar effects on hair growth as Dutasteride.
The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.
The conversation is about the potential benefits of Rapamycin for hair pigmentation and regeneration, based on effects observed in mice. The original poster is seeking personal experiences from others using Rapamycin for longevity.
The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.
The conversation discusses the potential of Verteporfin for hair regeneration and improving hair transplant surgery to leave no scars. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.
The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.
PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.
PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.
Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.
The conversation is about using topical finasteride or dutasteride with a testosterone and NPP cycle for hair loss. The planned treatment includes microneedling, minoxidil, pyrilutamide, and dutasteride applied topically.
A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.
A fake hair loss product called "PP405" is being humorously discussed, with users joking about its effectiveness and availability on resale websites. The consensus is that it's a scam, with some users sarcastically claiming miraculous results.
David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.
Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.